West Total Stockholder Equity vs Retained Earnings Analysis
WST Stock | USD 364.19 1.40 0.38% |
West Pharmaceutical financial indicator trend analysis is more than just analyzing West Pharmaceutical current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether West Pharmaceutical is a good investment. Please check the relationship between West Pharmaceutical Total Stockholder Equity and its Retained Earnings accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Total Stockholder Equity vs Retained Earnings
Total Stockholder Equity vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of West Pharmaceutical Total Stockholder Equity account and Retained Earnings. At this time, the significance of the direction appears to have totally related.
The correlation between West Pharmaceutical's Total Stockholder Equity and Retained Earnings is 0.99. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of West Pharmaceutical Services, assuming nothing else is changed. The correlation between historical values of West Pharmaceutical's Total Stockholder Equity and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of West Pharmaceutical Services are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Stockholder Equity i.e., West Pharmaceutical's Total Stockholder Equity and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.99 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from West Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into West Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, West Pharmaceutical's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 30.72 in 2024, whereas Enterprise Value is likely to drop slightly above 252.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 2.8B | 2.9B | 2.9B | 3.1B | Depreciation And Amortization | 126.1M | 120.6M | 137.3M | 144.2M |
West Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
West Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
West Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.3B | 2.8B | 3.3B | 3.6B | 3.8B | 4.0B | |
Short Long Term Debt Total | 329.3M | 325.7M | 325.3M | 317.9M | 309M | 227.6M | |
Other Current Liab | 145.4M | 226.9M | 259.7M | 228.1M | 236M | 247.8M | |
Total Current Liabilities | 341.6M | 503.4M | 594.1M | 519M | 671.8M | 705.4M | |
Total Stockholder Equity | 1.6B | 1.9B | 2.3B | 2.7B | 2.9B | 3.0B | |
Property Plant And Equipment Net | 909.4M | 1.0B | 1.1B | 1.3B | 1.5B | 1.6B | |
Net Debt | (109.8M) | (289.8M) | (437.3M) | (576.4M) | (544.9M) | (517.7M) | |
Retained Earnings | 1.5B | 1.8B | 2.5B | 3.0B | 3.5B | 3.7B | |
Cash | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 896.6M | |
Non Current Assets Total | 1.3B | 1.4B | 1.6B | 1.7B | 1.9B | 2.0B | |
Non Currrent Assets Other | 20.5M | 29M | 36.3M | 55.9M | 38.4M | 32.0M | |
Cash And Short Term Investments | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 896.6M | |
Net Receivables | 319.3M | 385.3M | 489M | 507.4M | 512M | 537.6M | |
Liabilities And Stockholders Equity | 2.3B | 2.8B | 3.3B | 3.6B | 3.8B | 4.0B | |
Non Current Liabilities Total | 426.6M | 435.9M | 384.3M | 412.9M | 276.7M | 307.8M | |
Inventory | 235.7M | 321.3M | 378.4M | 414.8M | 434.7M | 456.4M | |
Other Current Assets | 64.6M | 51.6M | 112M | 103M | 135.8M | 142.6M | |
Other Stockholder Equity | 154.6M | 99.6M | 19.5M | (138.7M) | (517.4M) | (491.5M) | |
Total Liab | 768.2M | 939.3M | 978.4M | 931.9M | 948.5M | 995.9M | |
Total Current Assets | 1.1B | 1.4B | 1.7B | 1.9B | 1.9B | 2.0B | |
Short Term Debt | 11.9M | 12.4M | 53.5M | 18.2M | 151.7M | 159.3M | |
Intangible Assets | 29.8M | 30.5M | 23M | 18.4M | 15.1M | 14.3M | |
Accounts Payable | 156.8M | 213.1M | 232.2M | 215.4M | 242.4M | 254.5M | |
Property Plant And Equipment Gross | 909.4M | 1.0B | 2.2B | 2.4B | 2.8B | 3.0B | |
Accumulated Other Comprehensive Income | (149.6M) | (110.6M) | (159.6M) | (183M) | (143.8M) | (151.0M) | |
Other Liab | 109.2M | 117M | 112.5M | 113.2M | 130.2M | 107.9M | |
Other Assets | 43M | 52.3M | 104.4M | 104M | 93.6M | 47.0M | |
Long Term Debt | 255M | 252.9M | 208.8M | 206.7M | 72.8M | 69.2M | |
Good Will | 107.8M | 111.1M | 109.9M | 107.3M | 108.5M | 103.1M | |
Treasury Stock | (118.1M) | (167.7M) | (229.5M) | (370.9M) | (333.8M) | (317.1M) | |
Property Plant Equipment | 839.3M | 943.2M | 1.1B | 1.2B | 1.3B | 1.4B | |
Current Deferred Revenue | 27.5M | 51M | 48.7M | 57.3M | 41.7M | 38.2M | |
Net Tangible Assets | 1.4B | 1.7B | 2.1B | 2.6B | 2.9B | 3.1B | |
Retained Earnings Total Equity | 1.5B | 1.8B | 2.5B | 3.0B | 3.4B | 3.6B | |
Long Term Debt Total | 255M | 252.9M | 208.8M | 206.7M | 186.0M | 209.4M | |
Capital Surpluse | 272.7M | 267.3M | 249M | 232.2M | 267.0M | 223.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether West Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if West Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about West Pharmaceutical Services Stock. Highlighted below are key reports to facilitate an investment decision about West Pharmaceutical Services Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for West Stock analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Transaction History View history of all your transactions and understand their impact on performance | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is West Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of West Pharmaceutical. If investors know West will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about West Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.78 | Earnings Share 7.57 | Revenue Per Share 39.549 | Quarterly Revenue Growth (0.03) |
The market value of West Pharmaceutical is measured differently than its book value, which is the value of West that is recorded on the company's balance sheet. Investors also form their own opinion of West Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is West Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because West Pharmaceutical's market value can be influenced by many factors that don't directly affect West Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between West Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if West Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, West Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.